90Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates

90Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates

Purpose: B-cell non-Hodgkin lymphomas (NHLs) are significant contributors to cancer-related mortality. In this single-arm, retrospective cohort study, we aimed to examine the outcomes of a radioimmunotherapeutic modality, 90Y-labeled ibritumomab tiuxetan (90YIT) in B-cell NHLs. Methods and Materials...

Descrición completa

Detalles Bibliográficos
Main Authors: Zsolt Szakács, MD, PhD, Amar Lal, MD, Jorgen Kristensen, MD, PhD, Nelli Farkas, PhD, Zsombor Ritter, MD, Szabolcs Kiss, MD, Hussain Alizadeh, MD, PhD, Anett Balikó, MD
Formato: Artigo
Idioma:English
Publicado: Elsevier 2022-09-01
Series:Advances in Radiation Oncology
Acceso en liña:http://www.sciencedirect.com/science/article/pii/S2452109421002402

Internet

http://www.sciencedirect.com/science/article/pii/S2452109421002402

Títulos similares